Oragenics
OGEN
11 hedge funds and large institutions have $2.73M invested in Oragenics in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
57% more funds holding
Funds holding: 7 → 11 (+4)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
11% less capital invested
Capital invested by funds: $3.06M → $2.73M (-$328K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$113K |
| 2 |
VF
Virtu Financial
New York
|
+$71K |
| 3 |
MP
MSD Partners
New York
|
+$63.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.2K |
| 5 |
Barclays
London,
United Kingdom
|
+$18.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$39.5K |
| 2 |
Citigroup
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TS
1
Third Security
Radford,
Virginia
| $2.14M | – | – | – |
|
2
Fidelity Investments
Boston,
Massachusetts
| $230K | – | – | – |
|
|
3
Morgan Stanley
New York
| $107K | +$113K | +43 | New |
|
|
VF
4
Virtu Financial
New York
| $83K | +$71K | +27 | +450% |
|
|
MP
5
MSD Partners
New York
| $59K | +$63.1K | +24 | New |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $52K | +$55.2K | +21 | New |
|
7
Bank of New York Mellon
New York
| $28K | – | – | – |
|
|
8
Barclays
London,
United Kingdom
| $20K | +$18.4K | +7 | +700% |
|
9
UBS Group
Zurich,
Switzerland
| $7K | +$5.26K | +2 | +200% |
|
|
IA
10
IFP Advisors
Tampa,
Florida
| $4K | -$39.5K | -15 | -88% |
|
|
HWM
11
Holloway Wealth Management
Gainesville,
Florida
| $2K | – | – | – |
|
12
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $2K | +$2.63K | +1 | New |
|
13
BlackRock
New York
| $1K | – | – | – |
|
|
14
Citigroup
New York
| – | -$2K | – | – |
|
OGEN Hedge Fund Activity: Q2 2018 in Review
11 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q2 2018, worth a combined $2.73M — down 11% from $3.06M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new OGEN positions and 0 closed out — a net gain of 4 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $113K. The largest seller was IFP Advisors, cutting an estimated $39.5K.
- 11 institutional investors held Oragenics (OGEN) as of Q2 2018, up from 7 in Q1 2018.
- Funds reported $2.73M of Oragenics stock for Q2 2018, down 11% quarter-over-quarter.
- 4 funds opened new Oragenics positions in Q2 2018 and 0 closed out, a net change of +4 holders.
- The largest Oragenics buyer in Q2 2018 was Morgan Stanley, an estimated $113K added.
- The largest Oragenics seller in Q2 2018 was IFP Advisors, an estimated $39.5K sold.
Based on aggregated 13F filings for Q2 2018.